Akums Drugs Pharma Scores 63 ESG Rating from NSE Analytics

Akums Drugs and Pharmaceuticals Ltd. has reported receiving an ESG rating of 63 for the fiscal year 2024-25 from NSE Sustainability Ratings & Analytics Limited. The company noted the disclosure date was May 8, 2026.

Akums Reports ESG Score

Akums Drugs and Pharmaceuticals Ltd. has disclosed its ESG rating for the current fiscal year, FY2024-25, which stands at 63. The assessment was provided by NSE Sustainability Ratings & Analytics Limited. The company emphasized that this rating was voluntarily assigned based solely on publicly available information.

Investor Focus on Sustainability

Investors worldwide are increasingly prioritizing companies with strong Environmental, Social, and Governance (ESG) performance. Strong ESG ratings can enhance a company's reputation and potentially improve its access to capital and favorable lending terms. Akums' disclosure signals its engagement with growing sustainability reporting expectations within the industry.

About Akums and Industry Trends

Akums Drugs and Pharmaceuticals Ltd. is a significant contract manufacturer within India's pharmaceutical sector, operating advanced facilities that produce a broad range of formulations for domestic and international markets. The global pharmaceutical industry, including in India, is under increasing pressure to adopt and report on ESG principles. Consequently, many major listed Indian pharmaceutical companies now publish detailed sustainability reports.

Potential Impact and Next Steps

This ESG rating may draw greater attention to Akums' sustainability practices from investors and stakeholders. It could encourage the company to enhance its proactive disclosure of ESG data moving forward. The rating might be viewed as an initial step towards integrating ESG more formally into Akums' business strategy. Shareholders and analysts will likely seek consistent performance and more details on the company's specific ESG initiatives.

Rating Limitations

It is important to note that the ESG rating was voluntarily assigned by the agency and based on publicly available information. Akums did not formally engage the agency for this assessment. This suggests the rating may not represent a fully comprehensive, in-depth evaluation of the company's ESG practices.

Industry Peers and Reporting

Akums operates as a contract manufacturer, but its broader industry peers include major integrated pharmaceutical companies such as Cipla Ltd., Sun Pharmaceutical Industries Ltd., and Dr. Reddy's Laboratories Ltd. Many of these listed peers actively publish detailed annual sustainability reports. A direct comparison of Akums' '63' score with peers is challenging due to differences in rating methodologies and assessment scopes.

Looking Ahead

Investors and stakeholders will be monitoring Akums Drugs for future ESG disclosures and sustainability reports. It will be important to observe if the company engages more formally with ESG rating agencies or frameworks. Tracking how investor perception evolves regarding Akums' sustainability efforts and assessing if ESG considerations become more prominent in the company's strategic communications will also be key.